The primary objectives of this trial are: 1) to evaluate the safety of NONA-L-ARGININE in ex
vivo application to saphenous vein segments prior to grafting; and, 2) to obtain preliminary
data on the biological effects of NONA-L-ARGININE, as compared to placebo, in the prevention
of neointimal hyperplasia.